U.S. FDA approves Inluriyo (imlunestrant) in combination with Verzenio (abemaciclib) for adults with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer
RegulatoryapprovedInluriyoVerzenioPositive
AI Analysis
Summary
The U.S. FDA approved Inluriyo (imlunestrant) in combination with Verzenio (abemaciclib) for adults with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer. The combination demonstrated clinical benefit in the Phase 3 EMBER-3 trial, with Inluriyo plus Verzenio doubling median progression-free survival.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Met
Outcome Details
FDA approval of Inluriyo (imlunestrant) in combination with Verzenio (abemaciclib) for adults with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer
Importance:9/10
Sentiment:
0.90
FDA approvalbreast cancercombination therapyPhase 3
Read the original article
Published by PR Newswire Clinical Trials on September 18, 2026 5:54 PM